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XIAPBackground: Prominence of glycolysis in glioblastomas may be non-speciﬁc or a feature of oncogene-related
subgroups (i.e. ampliﬁed EGFR, etc.). Relationships between ampliﬁed oncogenes and expressions of metabolic
genes associated with glycolysis, directly or indirectly via pH, were therefore investigated.
Methods: Using multiplex ligation-dependent probe ampliﬁcation, copy numbers (CN) of 78 oncogenes were
quantiﬁed in 24 glioblastomas. Related expressions of metabolic genes encoding lactate dehydrogenases
(LDHA, LDHC), carbonic anhydrases (CA3, CA12), monocarboxylate transporters (SLC16A3 orMCT4, SLC16A4 or
MCT5), ATP citrate lyase (ACLY), glycogen synthase1 (GYS1), hypoxia inducible factor-1A (HIF1A), and enolase1
(ENO1) were determined in 22 by RT-qPCR. To obtain supra-glycolytic levels and adjust for heterogeneity,
concurrent ENO1 expression was used to mathematically transform the expression levels of metabolic genes al-
ready normalized with delta-delta crossing threshold methodology.
Results: Positive correlations with EGFR occurred for all metabolic genes. Signiﬁcant differences (Wilcoxon Rank
Sum) for oncogene CNgains in tumors of at least 2.00-fold versus less than 2.00-fold occurred for EGFRwith CA3's
expression (p b 0.03) and for RNF139with CA12 (p b 0.004). Increased CN of XIAP associated negatively. Tumors
with less than 2.00-fold CN gains differed from those with gains for XIAP with CA12 (p b 0.05). Male gender
associated with CA12 (p b 0.05).
Conclusions: Glioblastomas with CN increases in EGFR had elevated CA3 expression. Similarly, tumors with
RNF149 CN gains had elevated CA12 expression.
General signiﬁcance: In larger studies, subgroups of glioblastomas may emerge according to oncogene-related
effects on glycolysis, such as control of pH via effects on carbonic anhydrases, with prognostic and treatment
implications.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Increased reliance on glycolysis for ATP is a deﬁning feature of
malignancies, including the incurable, high-grade brain tumors known
as glioblastomas. Enzymes of the glycolytic pathway in tumors are
protected under conditions that are inhospitable for normal cells. In
previous studies of glioblastoma cells, we identiﬁed their pseudopodia
as being glycolytic subcellular domains that also contain oncogene
products, including increased Met [1] and phosphorylated EGFR.
Discovering increased anti-phosphotyrosine and anti-phosphoserine/
threonine-reactive bands on immunoblots of pseudopodia compared
to whole cells suggested to us that multiple oncogenes could be present
in glycolytic regions of these cells (unpublished). In view of the
functional roles and associations of the proteins encoded by oncogenes
in enhancement of tumors and their malignant behavior, oncogenesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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glycolysis. Oncogenes and their products potentially increase protection
of glycolytic enzymes from the protons released by non-aerobic produc-
tion of ATP involving lactic acid.
Copy numbers (CNs) of ampliﬁed oncogenes and expression levels
of metabolic genes can be determined in the same tumors to detect
functional associations. PCR techniques quantify gene expression and
CN with impressive sensitivity. Heterogeneity within each tumor due
to a malformed vasculature, etc. leads to ﬂuctuation in metabolism. To
account for heterogeneity in levels of glycolytic activity and obtain
supra-glycolytic levels, the expression results for metabolic genes in
tumor samples were transformed mathematically to levels indicated
by expression of ENO1 that encodes enolase 1, the major isoform of
enolase in glioblastomas. Enolase catalyzes the ninth of ten steps in
the traditional glycolytic pathway. The expression of ENO1 in tumors,
given as a value relative to normal brain expression, was used to scale
the expression levels of other metabolic genes in the same tumor. The
metabolic genes' expression levels were transformed to be multiples
of concurrent ENO1 levels. Studies have shown that ENO1 is seldom
lost in high grade brain tumors. ENO1was retained in 98.6% of glioblas-
tomas with some variation in expression levels noted [2]. Expressing
each metabolic gene as a multiple of ENO1's expression level in the
same sample led to the discovery of positive correlations between
oncogene CNs and the expression of metabolic genes in this study.
Possibly glioblastomas harbor functional subgroups deﬁned by changes
in CN of oncogenes.
Not surprisingly, including control of pH among the functional
choices of genes to study yielded signiﬁcant results. Warburg utilized
large amounts of bicarbonate in hismodel of cancer [3]. The bicarbonate
buffer system is the most important physiologic buffer. It controls the
body's pH via independent regulation of its components, carbon dioxide
and bicarbonate, by the lungs and kidneys, respectively, thus providing
tremendous capacity [4]. Determining how tumors take advantage of
the circulating 4300 mmoles of bicarbonate that the kidneys ﬁlter and
mostly recycle daily [5] is urgently needed. Our study identiﬁed multi-
ple associations between EGFR, RNF139, and XIAP oncogenes and gender
with expression levels of two carbonic anhydrases that catalyze
interconversions among components of the bicarbonate buffer system.
2. Materials and methods
2.1. Patients in the study
With patient and Institutional Review Board approval, frozen
samples of glioblastomas resected from 25 adult patients during the
time interval, 2002–2008, were obtained from the University of Pitts-
burgh Brain Tumor Tissue Bank. Clinical information for 24 patients
included a mean age of 62.9 yr., range 19–81 yr., M:F = 11:13, andTable 1
Clinical information regarding glioblastoma (GB) patients.
GB Age
(yrs)
Sex GB Age
(yrs)
Sex
01 36 M 13 66 M
02 57 M 14 53 M
03 77 F 15 69 F
04 58 F 16 19 M
05 43 F 17 78 F
06 59 F 18 65 M
07 74 F 19 62 F
08 69 F 20 69 F
09 Unka Unk 21 80 M
10 46 M 22 81 F
11 69 M 23 55 F
12 64 M 24 80 M
25 81 F
a Unknown data.data for speciﬁc patients are listed (Table 1). Only one case, GB25, was
unsatisfactory for all parts of the study.
2.2. Multiplex ligation-dependent probe ampliﬁcation (MLPA) analysis of
oncogenes
Copy number (CN) was determined for each of seventy-eight
oncogenes (AKT1, AURKA, BCAR3, BCAS1 and 2, BCL2, BCL2A1, BCL2L1,
11, 13, and 14, BCL6, BCLG, BIRC2, 3, and 5, BRAF, BRMS1, CCNA1, CCND1
and 2, CCNE1, CDK4 and 6, CENPF, CTTN, CYP27B1, EGFR, ERBB2 and 4,
ESR1, EVI1, FGF3 and 4, FGFR1, GNAS, GSTP1, HMGA1, IGF1R, IGFBP2, 4
and 5, IRS2, JAK2, MDM2 and 4, MET, MMP7, MOS, MYCL, MYBL1 and 2,
MYC, MYCN, NAIP, NFKBIE, NRAS, NTRK1-3, PDGFRA and B, PIK3C2B,
PIK3CA, PPM1D, PSMB4, PTK2, PTP4A3, PTPN1, RELA, RNF139, RUNX1,
SERBINB2, 7, and 9, TERT, TOM1L2, UCKL1, and XIAP). Multiplex
ligation-dependent probe ampliﬁcation (MLPA) was successfully
performed in 24 tumors (GB01-GB24) to obtain CN data. Normal brain
(NB) from the occipital lobe of an 82 yr. old female (Biochain, Hayward,
CA) was used to normalize tumor DNA results for each oncogene's CN.
All tumors were analyzed concurrently with NB in the MLPA assays.
Brieﬂy, in MLPA, DNA (200 ng) from tumor samples and NB was
denatured at 98 °C and hybridized with MLPA probes (P171, P172,
P173 Tumor Gains kits, MRC-Holland, The Netherlands) for genes that
are known to be ampliﬁed in tumors. Hybridization occurred during
16–20 h at 60 °C. Ligations with Ligase65 (MRC-Holland) were at
54 °C for 15 min followed by 98 °C for 5 min. Ligation products were
ampliﬁed with PCR primers and polymerase for 35 cycles (30 s 95 °C,
30 s 60 °C, 60 s 72 °C) and then 20 min at 72 °C at the end using a
thermocycler (MasterCycler personal Eppendorf, Hamburg, GM). PCR
products were separated and analyzed via capillary electrophoresis
using the SS600 Fragment Analysis option with ﬂuorescent signal
detection on a CEQ8000 instrument (Beckman-Coulter, Fullerton, CA)
using themanufacturer's reagents and size standards. Stuffer sequences
incorporated into PCR probes of speciﬁc lengths identiﬁed the ampliﬁed
products of PCR reactions in regard to each gene. Peak heights reﬂected
initial amounts of DNA. Slightly less efﬁcient PCR of longer amplicons
accounted for minor reductions in peak heights that were corrected
with NB by dividing tumor oncogene CN by NB CN for the same
oncogene. These methods have been previously described more fully
[6,7]. Note that in earlier studies BCL2L14 was listed as BCLG/BCL2L14,
CTTN as EMS, NAIP as BIRC1, XIAP as BIRC4, and UCKL1 as FLJ20517.
Some cytogenetic loci for various genes have also changed and are
given in this paper as they are currently listed on the Online Mendelian
Inheritance in Man (OMIM) or HUGO Gene Nomenclature Committee
(HGNC) websites, http://www.omim.org/ and http://www.genenames.
org/, respectively.
2.3. RT-qPCR for metabolic and growth factor (MTB/GF) gene expression
Numerous genes encoding proteins that favor glycolysis under
adverse conditions, including acidosis and intermittent disconnection
from the blood supply (i.e. invasive cell migration), were considered
among geneswhose encoded proteins enable glycolysis during hypoxia.
Using early (2007–2008) versions of the Repository of Molecular Brain
Neoplasia Database (REMBRANDT) [8], ENO1 was chosen to represent
the expression levels of genes encoding enzymes in the energy genera-
tion phase of glycolysis and then served to transform expressions
of other metabolic genes and growth factor genes. Nine other genes
(ACLY, CA3, CA12, GYS1, HIF1A, LDHA, LDHC, SLC16A3 (or MCT4), and
SLC16A4) were chosen as genes of interest (GOI) from the functionally
relevant metabolic groups of genes. Two growth factors, EGF and
PDGFA, were also chosen for this study. For each group of genes (glucose
transport, glycolysis, mitochondria, links between metabolic pathways,
fat metabolism, control of pH/lactate, glycogen metabolism, gluconeo-
genesis, and growth factors) and for each individual gene, the preva-
lence of 2-fold or greater elevations in glioblastomas, the likelihood
3M.E. Beckner et al. / BBA Clinical 5 (2016) 1–15of a glioma being a glioblastoma if an elevation in expression was
present, signiﬁcantly poorer survival in glioblastomas with elevations
(see Section 3.2), as well as functional relevance based on previous
studies, were considered in compiling a list of 12 metabolic/growth
factor (MTB/GF) genes to study for associations with oncogenes. Data
for the MTB/GF genes in their respective groups and the controls are
given in Section 3.2. Since ENO1was used for MTB/GF gene transforma-
tions and SLC16A4's locus was potentially within an oncogene amplicon
(see Section 3.1), data is reportedmost comprehensively for eight of the
ten metabolic genes. The RNA-derived cDNAs were prepared from
tumor samples and the reference pooled non-malignant brain RNA
from 23 adults, mean 68.3 yr., range 23–86 yr. of age. Sufﬁcient RNA
was obtained from 22 tumors (GB01-08 and GB10-23) for analysis
(M:F = 10:12, 19–80 yr. of age). Template cDNAs in each tumor and
the reference were tested in triplicate for quantitative expression levels
of MTB/GF genes and two housekeeping genes (HKGs), which were
ACTB and GAPDH on 96 well plates (SABioSciences Corp. Qiagen, Valen-
cia, CA), using an ABI 7500 Prism thermocycler (Applied BioSystems,
ThermoFisher Scientiﬁc, Waltham, MA). The delta-delta crossing
threshold (ddCt) method was used to determine fold increases in the
tumors compared to reference derived cDNA with averaged HKGs
used for normalization. Each dCt equaled Ct(MTB/GF)—average
Ct(HKG). The ddCt for each gene equaled dCt(tumor sample) −
dCt(reference non-malignant brain). The fold-change for each MTB/GF
gene compared to the normal reference was equal to 2−ddCt. This
methodology and the HKGs have been more fully described [9]. After
normalizing with the HKGs, MTB/GF gene expression levels were
transformed (division by concurrent expression of ENO1). Results for
each MTB/GF gene were used for comparisons with CN of oncogenes in
Fisher's Exact tests, correlations, and Wilcoxon Rank Sum comparisons.
2.4. Detection of MTB gene relationships with the presence of any ampliﬁed
oncogenes
Tumors were initially stratiﬁed according to whether they had
oncogene(s) ampliﬁed at 3.00-fold or greater levels (Yes or No) to
facilitate analysis with Fisher Exact tests. The results for each MTB/GF
gene were used to determine tumor membership in Group (+) if the
MTB/GF gene had ≥1.10× (times) ENO1 expression and Group (−) if
the MTB/GF gene had b1.10× ENO1 expression levels. The cut-off of
1.10× expression of ENO1 was chosen to form the groups with no
other cut-offs attempted to avoid selection bias. The 1.10× threshold
was used only for the Fisher Exact tests reported in Section 3.4.
2.5. EGFR ﬂuorescence in situ hybridization (FISH)
A frozen tissue sample available on GB06 was evaluated for EGFR
signals with ﬂuorescence in situ hybridization (FISH). The FISH probes
for the EGFR band region, 7p11.2–7p12 and a control locus, 7p11.1–
q11.1, D7Z1, (Vysis Locus Speciﬁc Identiﬁer EGFR SpectrumOrange and
CEP 7 SpectrumGreen, respectively, Abbott Molecular Inc., Des Plaines,
IL) were hybridized to interphase nuclei in a 5 μm section overnight.
Un-hybridized probes were washed away. Diaminophylindole (DAPI)
ﬂuorescent blue (Abbott Molecular) stained the nuclei. Slides were
scanned on a ﬂuorescent microscope (Leica DMR, Wetzlar, GM) for
analysis with images captured using a digital camera (Applied Imaging,
San Jose, CA) and CytoVision v4.02 imaging software (Applied Imaging).
The methodology was described in a previous study [6].
2.6. Statistical tests
The Fisher's Exact tests were described in Section 2.4. Pearson's
correlation coefﬁcients were calculated to detect positive and negative
correlations between expression values of MTB/GF genes and CN of
oncogenes. Correlations were also performed for 3 genes in the 8q
amplicon with each other. Wilcoxon Rank Sum comparisons wereperformed to detect associations with metabolic gene expression in
the group of oncogenes deﬁned by (1) exhibiting at least one 3.00-
fold CN gain among all the tumors and (2) whose data yielded two
groups of comparable sizes (10 and 12, 9 and 13, or 8 and 14 tumors)
when oncogene CN gains of 2.00-fold or greater were considered.
Associations with metabolic gene expressions have p-values stated for
trends and signiﬁcance levels less than 0.05. Also, chi square analyses
were performed on tumors in the REMBRANDT database during the
selection of genes for expression analysis, as described in the Results
section (end of Section 3.2).
3. Results
3.1. Oncogene ampliﬁcations detected with MLPA
Twenty-four glioblastomas (GB1–GB24) assayed with MLPA for the
CN levels of 78 oncogenes yielded ampliﬁcations, 3.00-fold or greater,
in 18 glioblastomas for one or more of twenty oncogenes, listed as
follows: BCL2A1, CCND1, CCND2, CDK4, CDK6, CTTN, CYP27B1, EGFR,
EVl1, FGF3, FGF4, GNAS, MDM4, MOS, MYC, PDGFRA, PIK3C2B, PIK3CA,
RNF139, and XIAP. Low level gains in CN that did not achieve a 3.00-
fold threshold also occurred frequently. For the twenty oncogenes
with at least one 3.00-fold ampliﬁcation in the tumors, all of the CN
gains for each one that were 2.00-fold or greater are shown at their
chromosomal loci (Fig. 1). Locations of MTB/GF genes for which only
RNA expression data were determined in the study are also included.
Each of the 24 glioblastomas tested had at least one of the CN gains
shown. Genes not ampliﬁed at or beyond the 3.00-fold threshold in at
least one tumor are not shown. Tumors with CN gains of EGFR also
had CN gains of one to seven other oncogenes among those shown
(Fig. 1). Twelve genes, whose gains were always below 3.00-fold
among the glioblastomas, included NRAS (1p13.2), BCAS2 (1p13.2),
ERBB4 (2q34), BCL6 (3q27.3), NAIP (5q13.2), MET (7q31.2), BRAF
(7q34), MDM2 (12q15), PPM1D (17q23.2), BCL2L1 (20q11.21), AURKA
(20q13.2), and RUNX1 (21q22.12), in at least one of 23 tumors. Of
these, MDM2 was co-ampliﬁed along with CYP27B1 and CDK4 nearby
on chromosome 12 in GB19, and with only CYP27B1 in GB14. These
ﬁndings are consistent with the complexity of the 12q13-15 amplicon
described in glioblastomas [10]. Also, AURKA was co-ampliﬁed with
nearby GNAS on chromosome 20 in GB06.
It was noted that near or at the locus for SLC16A4 (1p13.3), CN gains
occurred for oncogenes,NRAS (1p13.2) and BCAS2 (1p13.3). Although re-
sults for SLC16A4 are included when those for all the MTB/GF genes are
listed in tables, they are not shown when results of metabolic genes are
highlighted as a group (eight genes remaining) in the following ﬁgures
due to the possibility that SLC16A4was a bystander in an amplicon con-
taining the oncogenes, NRAS and BCAS2. Also, deletions of oncogenes de-
tected are not reported in this study. An example of MLPA ampliﬁcation
results for PDGFRA and EGFR are shown for GB06 with FISH signals for
EGFR in the frozen sample included as an insert (Fig. 2).
3.2. Expression of metabolic/growth factor (MTB/GF) genes in REMBRANDT
Speciﬁc members of functional groups and gene families were
chosen for study of their expression levels in samples of glioblastomas
based on queries of the REMBRANDT database of brain tumors [8] and
their potential support of glycolysis (Fig. 3a).
The highest proportions of 2-fold increased gene expressions
occurred among the following functional groups: the energy generation
phase of glycolysis, anaerobic glycolysis, upregulation of glycolysis,
links between metabolic pathways, control of pH/lactate, glycogen
metabolism, and growth factors. Within four of these groups, ENO1,
LDHC, CA3, and ACLY had the greatest numbers of elevations for
expression.
Additionally, in regard to the anaerobic glycolysis group, elevations
of LDHA expression levels at least 2-fold were present in 14 of all the
Fig. 1. Loci of ampliﬁed oncogenes and metabolic/growth factor genes. The chromosomal loci (red rectangles) of twenty oncogenes ampliﬁed at least 3.00-fold and metabolic/growth
factor (MTB/GF) genes are shown. The copy number (CN) ampliﬁcation of oncogenes in each glioblastoma (GB) are depicted with small solid black rectangles (1.00 times normal per
rectangle) and open arrows (10.00 times normal per arrow) as indicated in comparison to normal brain DNA. The highest CN gains occurred for EGFR. The superscript (†) indicates the
MTB/GF genes with expression data but no CN data.
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that the tumor was a glioblastoma. The chances of a glioma with 2-fold
or greater elevations of LDHC or ENO1 for being a glioblastoma were
85.7% and 89.3%, respectively. Therefore LDHA was also included.
Results for CA12 and SCL16A4 (Fig. 3b)were comparable to CA3's results,
along with impressive signiﬁcantly poorer survival results at high
expression levels, therefore they were also included. The well-known
function of the protein encoded by SLC16A3 (better known as MCT4)
and occurrence of its results within the range of the other chosenmem-
bers in this functional group warranted its inclusion.
Within the glycogen metabolism group, GYS1, GBE, and PYGL had at
least 2-fold elevations in 36, 101, and 114 gliomas, respectively, with
poorer Kaplan Meier survival in all gliomas for each of the three genes
at such signiﬁcant levels that their p-values were all given as 0.0. Thechances of the elevations occurring in a glioblastoma, when present in
a glioma, were 88.9%, 73.3%, and 70.2%, respectively, for GYS1, GBE1,
and PYGL. With this data, alongwith functional data reported previously
[11], GYS1 was chosen to study. Elevations of at least 2-fold expression
among the growth factors, EGF, PDGFA, TGFB1, and TGFB2 occurred in
32, 52, 58, and 66, respectively, of all gliomas so the tumors with eleva-
tions were also glioblastomas at rates of 75.0%, 76.9%, 70.7%, and 74.2%,
respectively. Considering this data along with the abundance of litera-
ture supporting their roles in brain tumors, EGF and PDGFA, were cho-
sen. Also, later searches showed that increased expression of EGF was
present in a higher percentage of glioblastomas than the 2007
REMBRANDT data indicated. The well-known regulator of glycolysis in
hypoxia, HIF1A, was also included. Functions of the proteins encoded
by the MTB/GF and control genes are given (Table 2).
Fig. 2.Quantiﬁedoncogenes inGB06. An example ofmultiplex ligation-dependent probe ampliﬁcation (MLPA) results for 78 oncogenes in one glioblastoma. Its high level ampliﬁcations of
PDGFRA and EGFRwere readily detected as ﬂuorescence signals from each of the 2 sets of probes used for each oncogene. The two-fold elevations in tumor versus normal brain were de-
tected usingmathematical comparisons described in Section 2.2. The red and blue lines represent tumor and normal DNA, respectively. Also, the inset at the top shows ﬂuorescence in situ
hybridization (FISH) signals for EGFR (red) in two cells of the frozen tissue sample used for MLPA. The nuclei stained blue with diaminophylindole (DAPI).
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survival in all gliomas was reported in the database for ACLY, GYS1,
ENO1, and HIF1A, at 2 or 3-fold levels of increased gene expression.
The other chosen metabolic genes, CA3, CA12, SLC16A3 (or MCT4),
SCL16A4, LDHA, and LDHC, had signiﬁcantly poorer survival in
glioblastomas with increased expression at levels that varied from 2 to
10-fold above normal. Also, EGF and PDGFA had signiﬁcantly poorer
survival associated with elevated expression levels in all gliomas and
glioblastomas and in all gliomas, respectively. Additionally, by chi
square analyses the likelihood for elevated levels of the genes to occur
in a glioblastoma that also contained a 2-fold elevation in expression
of ENO1 (our putative indicator of glycolytic activity) was p b 0.05 for
ACLY, GYS1, SLC16A4, LDHA, and HIF1A. Trends for PDGFA, LDHC,
SLC16A3 (orMCT4), and EGF occurred with p-values of 0.05, 0.05, 0.14,and 0.16, respectively. Speciﬁc p-values for the expression of CA3 at 3-
fold, 7-fold, and 10-fold elevations to occur in tumors with 2-fold
elevations in ENO1's expression were 0.48, 0.27, and 0.25, respectively.
The downward trend in p-values for fold elevations of CA3 extending
to the highest limit in the database was valued. The p-values for expres-
sion of CA12 at 2-fold, 3-fold, and 5-fold elevations to occur in tumors
with 2-fold elevations in ENO1's expression were 0.04, 0.002, and
0.0001, respectively.
3.3. MTB/GF gene expression mathematically transformed by concurrent
ENO1 levels
RNA from22 glioblastomas in this study yielded results that could be
analyzed with RT-qPCR. One of the unsatisfactory specimens (GB25)
Fig. 3. Searches for MTB/GF genes of interest (GOI) in the REMBRANDT database. Genes were chosen based on functional relevance and REMBRANDT [8] expression data. Section 3.2
explains the selection of GOI indicatedwith red arrows in detail. (a) Functional groupings. (b) Utilization of expression levels above two-fold in selection of GOI in the carbonic anhydrase
and solute carrier 16 families of genes. Expression levels that had signiﬁcant p-values (b0.05) for poorer survival (KaplanMeier) are bolded. The full gene names are as follows: ACLY (ATP
citrate lyase), ACTB (actin B), ALDOA (aldolase A), CA (carbonic anhydrase), EGF (epidermal growth factor), ENO1 (enolase 1), FBP1 (fructose 1,6 bisphosphatase), FOXC2 (forkhead box C2),
GAPDH (glyceraldehyde-3-phosphate dehydrogenase), GBE1 (glycogen binding enzyme), GCK (glucokinase),GPI (glucophosphoisomerase), GYS1 (glycogen synthase 1),HBEGF (heparin-binding
EGF like growth factor), HGF (hepatocyte growth factor), HIF1A (hypoxia-inducible factor 1, alpha subunit), HK (hexokinase), IGF2 (insulin-like growth factor II), LDH (lactate dehydrogenase),
ME1 (malic enzyme 1), PCK (phosphoenolpyruvate carboxykinase), PDGF (platelet-derived growth factor), PDHX (pyruvate dehydrogenase complex, component X), PFKFB4 (6-phosphofructo-
2-kinase/fructose-2,6 bisphosphatase 4), PGAM2 (phosphoglycerate mutase 2), PGK1 (phosphoglycerate kinase 1), PFKL (phosphofructokinase L), PKM2 (pyruvate kinase, muscle, 2), PYGL
(glycogen phosphorylase, liver), SDH (succinate dehydrogenase complex), SLC2 (solute carrier family 2), SLC16 (solute carrier family 16), TGFB (transforming growth factor, beta), and TPI1
(triosephosphate isomerase 1). Note that SCL16A3 is also known asMCT4 (monocarboxylate transporter 4).
6 M.E. Beckner et al. / BBA Clinical 5 (2016) 1–15was also unsatisfactory for MLPA when determining CN of oncogenes.
The concurrent values for expression of ENO1, ranging from 0.222 to
1.972 times normal, were used to transform the expression of each
MTB/GF gene to multiples of ENO1 to reﬂect their levels relative toglycolytic pathway activity to obtain the supra-glycolytic levels in
adjusting for tumor heterogeneity. The range of gene expression for
pathway activity was assumed to range from 0.222 to 1.972 times nor-
mal according to the values of ENO1. In a previous study the expression
Table 2
Functions of proteins encoded by metabolic and growth factor (MTB/GF) genes selected
for expression analysis and studies for associations with oncogenes.
1. ACLY, ATP citrate lyase Cleaves citric acid, synthesizes acetyl CoA
2. CA3, Carbonic anhydrase III Interconversions of CO2/HCO3− in cytoplasm
3. CA12, Carbonic anhydrase XII Interconversions of CO2/HCO3− at cell surface
4. ENO1, Enolase 1* Catalyzes ninth of ten steps in glycolysis
5. GYS1, Glycogen synthase 1 Synthesis of glycogen from simpler
carbohydrates
6. HIF1A, Hypoxia-inducible factor 1,
alpha subunit
Transcription factor, upregulates genes in
hypoxia
7. LDHA, Lactate Dehydrogenase A Interconversion of lactic acid and pyruvate
8. LDHC, Lactate Dehydrogenase Cǂ Interconversion of lactic acid and pyruvate
9. SLC16A3, Solute carrier family 16
(monocarboxylic acid transporter),
member 3. See protein name
Transports lactic acid and pyruvate across
membranes, protein called monocarboxylate
transporter 4 (MCT4)
10. SLC16A4, Solute carrier family 16
(monocarboxylic acid transporter),
member 4. See protein name
Transports lactic acid and pyruvate across
membranes, proteincalled monocarboxylate
transporter 5 (MCT5)
11. EGF, Epidermal Growth Factor Differentiation, etc.
12. PDGFA,Platelet-derived growth
factor, alpha polypeptide
Mesenchymal cell mitogenesis, etc.
13. ACTB, Actin B Structural, Housekeeping gene (HKG) for
RT-qPCR
14. GAPDH, Glyceraldehyde-3-
phosphate dehydrogenase
Glycolysis, Housekeeping gene (HKG) for
RT-qPCR
⁎ ENO1 was used to transform the expression levels of the other MTB/GF genes.
ǂ LDHC gene expression was originally thought to be limited to testes but has been
found in various types of malignancy.
Fig. 4. Expressions of MTB/GF genes and the effect of ENO1 transformation on ACLY in con-
sidering ENO1 as a candidate for MTB/GF transformations. (a) Comparisons of MTB/GF
gene expressions, including ENO1, prior to transformations in 22 glioblastomas (GBs).
Normal brain RNA was from pooled non-malignant brain tissue. Each gene's fold change
was obtained with the ddCt method described in Section 2.3. Means with 95% conﬁdence
intervals are shown for each gene. (b) Effects of ENO1when used to transform ametabolic
gene's expression data. On the left, the distribution of GBs, each identiﬁed with a 2-digit
number, is displayed according to ACLY's expression in each as a fold-change compared
to normal brain's ACLY RNA. The distribution shown on the right is according to each
tumor's expression of ACLY following transformation (division by concurrent ENO1
expression).
7M.E. Beckner et al. / BBA Clinical 5 (2016) 1–15of ACLY in this group of tumors was shown to correlate with concurrent
expression of ENO1 with no transformation performed and minus one
outlier [9]. Themean expressions of MTB/GF geneswith 95% conﬁdence
intervals (CI) are shown for all 22 glioblastomas (Fig. 4a).
The medians were within the lower halves of the 95% CI shown,
except for GYS1 and SLC16A3 (or MCT4). GYS1's median was in the
upper half of the 95% CI shown. SLC16A3's medianwas not in the gene's
95% CI and its 1st, 2nd (median), and 3rd quartiles were 0.668, 1.378,
and 3.340, respectively. CA3 with the largest degree of variability
shown had 1st, 2nd, and 3rd quartiles of 0.822, 1.019, and 2.568,
respectively. The distributions of 22 individual glioblastomas according
to their expression of ACLY, before and after transformation with
concurrent ENO1, are shown (Fig. 4b). The transformation produced
results in the same range with GBs more evenly distributed. However,
only 5 tumors retained the same level of expression and 7 shifted
more than 1 level of expression that is indicated on the x-axis.
Distributions of the glioblastomas according to their expressions of
eight metabolic genes, after transformation with concurrent ENO1 ex-
pressions can be compared to ACLY's distribution (Fig. 5).
3.4. Fisher's exact tests of MTB/GF gene expression with oncogene copy
number gains
Expression levels of the MTB/GF genes were transformed so that
levels above those attributed to ongoing glycolysis in a heterogeneous
tumor environment could be analyzed. After transforming their levels
to represent multiples of ENO1's concurrent expression, Groups (+)
and (−) were obtained for each MTB/GF gene based on whether its
expression level was equal to or greater than 1.10 times the expressionof ENO1 or not, respectively. Statistical signiﬁcance, p= 0.041 (Fisher's
Exact), for a difference was found for LDHC's Group (+) as shown
(Table 3, bottom row).
A tumorwith elevated LDHC levels had a greater likelihood of having
any 3.00-fold ampliﬁed oncogenes compared to Group(−) that was
comprised of tumors with LDHC levels below the cut-off. In Group(+)
for LDHC, 92% (11/12) of the tumors had ampliﬁed oncogenes versus
50% (5/10) in Group(−). The ampliﬁed oncogenes included EGFR,
EVI1, BCL2A1, and PIK3CA in 8, 7, 6, and 3 tumors, respectively, with
EGFR frequently being co-ampliﬁed. A strong tendency, p = 0.085
(Fisher's Exact), was also seen for the higher expression levels of LDHA
to have ampliﬁed oncogenes, with 86% of its Group(+) having them
versus 50% of its Group(−) tumors. Having only two glioblastomas in
CA12's Group(−) deﬁned by this threshold limited its analysis.
3.5. Correlations of CN gains for oncogeneswith expression ofMTB/GF genes
Each of the twenty oncogenes with at least one 3.00-fold elevation
among the glioblastomas exhibited positive correlations of their CN
gains with increased expression levels of at least two MTB/GF genes
(Table 4). All MTB/GF genes had positive correlations with CN of EGFR
and also for sums of CN for all 20 oncogenes (not shown). Among the
oncogenes, CCND1 had the next highest frequency of positive correla-
tions with MTB/GF genes and PIK3C2B, PIK3CA,MOS, RNF139, CYP27B1,
and BCL2A1, each correlated positively with seven MTB/GF genes.
Fig. 5.Distributions of glioblastomas according their expressions of eachmetabolic gene followingmathematical transformation by ENO1. Thiswasdescribed forACLY (Fig. 4b). Each tumor
is identiﬁed by a 2-digit number. The highest transformed values occurred for CA3, CA12, and SCL16A3 (orMCT4).
8 M.E. Beckner et al. / BBA Clinical 5 (2016) 1–15In contrast, XIAP exhibited predominantly negative correlations and
correlated positively with only two MTB/GF genes. Among the MTB/GF
genes, LCHC, LDHA, and GYS1 each had expression levels that correlated
positively with CN of fourteen oncogenes that are listed. All of the
metabolic genes had at least nine positive oncogene correlations each
whereas the growth factor genes each had ﬁve. The highest individual
correlation of a MTB/GF gene's expression with CN of an oncogene,
r = 0.63, occurred for PDGFA with CN of PDGFRA, the gene for one of
its receptors. The correlation of HIF1A's expression with CN of PDGFRA,
r = 0.52, was the next highest. The correlations of CA3's expression
with CN ofMOS andMYC, r= 0.46 for each, were noted with the reali-
zation that all 3 genes are located on 8q (Fig. 1). Patterns for positive
correlations in potential amplicons derived from 1q, 8q, 11q, and 12q
occurred (Table 4, bottom row).
Also, two patterns of possible functional relevance emerged
between metabolic genes and oncogenes. In one pattern, LDHA, LDHC,
CA3, CA12, and SLC16A3 (or MCT4), encoding proteins responsible for
generation of ATP in anaerobic glycolysis and buffering of the resultinghydrogen ions, shared positive correlations with MOS, RNF139, MYC,
PIK3C2B, CYP27B1, and CDK4 as well as with EGFR (Table 4 and
Fig. 6a). In a search for oncogenes that associate with glycolytic tumor
cell migration [12], a second oncogene pattern was characterized
by positive correlations of the lactate dehydrogenases and putative
metabolic adaptors,ACLY andGYS1 [9,11], for short-termor intermittent
dependence on glycolysis. This group consisted ofACLY,GYS1, LDHA, and
LDHC, positively correlating with the oncogenes, CCND1, CTTN, FGF3,
FGF4, and CCND2, as well as with EGFR, (Table 4 and Fig. 6b). Strong
negative correlations for ﬁve of the seven metabolic genes in these
two groups were found for CN of XIAP (Table 4 and Fig. 6c).
3.6. Associations of metabolic gene expressions with CN of oncogenes and
gender
Associationswith CN of several oncogenes and genderwere searched
for among eight metabolic genes, ACLY, CA3, CA12, GYS1, HIF1A, LDHA,
LDHC, and SLC16A3 using Wilcoxon Rank Sum comparisons. There
Table 3
Stratiﬁcation of each glioblastoma(GB) by the presence of ampliﬁed oncogenes and by expression levels of transformed metabolic/growth factor (MTB/GF) genes listed in the top row.
EachMTB/GF level was divided by concurrent expression of ENO1 to become amultiple of ENO1 expression. If the result was ≥1.10 (arbitrary threshold), then the GB is included in Group
(+) and otherwise is in Group (−). A signiﬁcant (*p b 0.05) association for LDHCwith the presence of ampliﬁed oncogenes and a trend for LDHAwere detected in the GBs.
GB Ampliﬁed oncogenes LDHC LDHA CA3 ACLY GYS1 SLC16A3
(MCT4)
SLC16A4
(MCT5)
HIF1A PDGFA EGF CA12
01 No − − − + + − + + − − +
02 Yes + + + + + + + + + + +
03 Yes + + + + + − − + + + −
04 No − − + − − + − − + + +
05 Yes + + + + + + + + + + +
06 Yes + + + + + + + + + + +
07 No + + + + + + + + + + +
08 Yes + + + + − + − − + − +
10 Yes + + + + + + + + + − +
11 Yes + + + + + + + + + − +
12 Yes + + + − + + + + − − +
13 Yes − + − − − + − + − − +
14 Yes + + + + − + + + − + +
15 No − − − − − − − + + + +
16 No − − − + − − − + − − +
17 Yes − − − − − − + − − − +
18 Yes + + + + + + + + + + +
19 Yes + + + + + + − + − − +
20 Yes − − − + + − − + + − +
21 No − + + − + + + − + − +
22 Yes − − − − + + + − − − −
23 Yes − − + + + − + + + + +
Total in Group (−) 10 8 7 7 7 7 8 5 8 12 2
Total in Group (+) 12 14 15 15 15 15 14 17 14 10 20
Numerators = Number of GBs with at least one ampliﬁed oncogene (3-fold or greater) in Group(−) or Group(+)
Group (−) 5/10 4/8 4/7 4/7 4/7 4/7 5/8 3/5 6/8 9/12 2/2
Group (+) 11/12 12/14 12/15 12/15 12/15 12/15 11/14 13/17 10/14 7/10 14/20
Fisher's Exact (p) 0.041* 0.085 0.213 0.213 0.213 0.213 0.273 0.319 0.376 0.354 0.519
9M.E. Beckner et al. / BBA Clinical 5 (2016) 1–15were 4 oncogenes, EGFR, RNF139, GNAS, and XIAP, whose CN gains were
sufﬁcient in number among the glioblastomas (Fig. 1) so that compari-
sons could be made using 2.00-fold CN gains as the threshold for inclu-
sion into one of two comparable-size groups for each of these four
oncogenes. Additionally, stratiﬁcation by gender (Table 1) also yielded
comparable size groups. Due to XIAP's location on the X chromosome,
gender is a contributing factor to XIAP's CN [13]. The gender ratio for
those without XIAP CN gains of at least 2.00-fold was M:F = 10:2 and
only females had XIAP CN gains that were 2.00-fold or more when stan-
dardized by normal DNA from a female for the CN studies. The largest
number of signiﬁcant associations occurred for CA12. Its associations
with RNF139's CN gains, XIAP's lack of CN gains, and male gender, had
p-values of 0.0037, 0.0426, and 0.0169, respectively, (Fig. 7a). Medians
for RNF139's CN gains, XIAP's lack of gains, and male gender, all 5.1424
(level of CA12 given as a multiple of concurrent ENO1's expression) are
shown as red dashed lines. The medians for CA12's transformed expres-
sion levels in the opposing groups were 1.6024, 1.7213, and 1.7213, re-
spectively, and are shown by blue dashed lines. A signiﬁcant
association occurred for CA3 with 2.00-fold or greater CN gains of EGFR,
p = 0.0249, with medians of 2.7444 and 1.2811 for CA3's transformed
expression levels in groups, with and without at least 2.00-fold CN
gains of EGFR, respectively, (Fig. 7b). Strong trends for associations
were found for transformed LDHA's expression levels with RNF139's
2.00-fold or greater CN gains, lack of XIAP's CN gains, and male gender
with p-values of 0.0950, 0.0804, and 0.1229, respectively, and a trend
was also detected for an association between transformed SLC16A3(or
MCT4)’s expression levels and RNF139's 2.00-fold or greater CN gains,
with a p-value of 0.11 (not shown). No signiﬁcant associations or trends
were found for GNAS using the 2.00-fold threshold for its CN gains with
metabolic genes (not shown).
4. Discussion
When respiration is inhibited, such as during hypoxia, the glycolytic
pathway lacksNAD+ frommitochondria. To compensate, large amountsof the organic acid, lactate, are produced frompyruvate via lactate dehy-
drogenases to maintain the NAD+ levels needed for continuous cycling
of non-aerobic glycolysis. The capacity for buffering hydrogen ions
becomes critical in glycolytic conditions due to susceptibility of phos-
phofructokinase and other glycolytic enzymes to inhibition by acidity
[14–17], in addition to the sensitivity of many cellular proteins to pH
changes. To control pH, there are alterations in carbonic anhydrase fam-
ily members, solute carrier (SLC) family members that transport
monocarboxylates, vacuolar type H+-ATPases, membrane sodium/
hydrogen exchangers, chloride/bicarbonate and sodium/bicarbonate
exchangers, etc. that occur in a cooperativemanner. Some of the regula-
tion is known, such as the effect of HIF-1α on carbonic anhydrase IX and
other proteins, but the complete picture is not known. The heightened
activity of tumor cells to manipulate their pH for compensatory
purposes is a hallmark of malignancy. This malignant feature has been
implicated in drug resistance and provides new treatment targets to
consider clinically [18–25].
The carbonic anhydrase family members are prominent mediators
of pH control in tumors. The amounts of bicarbonate, HCO3 −, needed
to buffer protonswould be depletedwithout replenishment by carbonic
anhydrases that catalyze interconversions of carbon dioxide and water
to bicarbonate and protons and vice versa via carbonic acid. The carbon-
ic anhydrases possess impressively rapid catalytic rates, up to a million-
fold maximal turnover rate per second for the carbonic anhydrase II
isoform in red cells [26]. The catalytic rate of CAIII (encoded by CA3)
in nucleated cells is slower but its activity can be enhanced by phos-
phates [27]. Also, isozyme-speciﬁc residues in the active site of CAIII,
when replaced by their counterparts in CAII, permit CAIII to achieve
the impressive kinetics of CAII [26,28,29]. Carbonic anhydrase III is a
major protein in muscle and myoepithelial cells [30–32]. Expression of
CA3 and other genes, including HIF1A, were signiﬁcantly augmented in
muscle of endurance runners exercising in hypoxia (14.5% oxygen)
[33]. In a separate study, repeated sprints by runners in hypoxia also
led to increased expression levels of CA3 [34]. Levels of CAIII also
increase with age in human muscle [35]. In the central nervous system,
Table 4
Correlations between individual MTB/GF genes and copy numbers (CN) of oncogenes, listed horizontally, in 22 glioblastomas. Expression values of MTB/GF genes after ddCt normalization were divided by concurrent expression levels of normalized
ENO1 to obtainMTB/GF values asmultiples of ENO1's expression prior to calculating correlations. Positive correlations less than 0.2 are indicated by ‘+’ and the negative ones are indicated by ‘-’. Genes are listed in the order of their chromosomal loci.
Similar patterns of correlations for potential amplicons comprised of oncogenes are indicated in the bottom row. Note that SLC16A3 is also known asMCT4.
MTB/GF genes listed below 1q32.1 3q26.2 3q26.32 4q12 7p11.2 7q21.2 8q12.1 8q24.13 8q24.21 11q13.3 12p13.32 12q14.1 15q25.1 20q13.32 Xq25
MDM4 PIK3C2B EVI1 PIK3CA PDGFRA EGFR CDK6 MOS RNF139 MYC CCND1 CTTN FGF3 FGF4 CCND2 CYP27B1 CDK4 BCL2A1 GNAS XIAP
1p13.3
SLC16A4 − − − + 0.28 + − + + − + − − − − − − 0.24 0.22 +
4q25
EGF − − + − 0.39 0.25 0.37 − − − − − − − − − − − − +
7p22.3
PDGFA − − − − 0.63 0.40 + − − − − − − − − − − + 0.27 −
8q21.2
CA3 0.33 0.34 0.24 + − + + 0.46 0.35 0.46 − − − − − 0.41 0.44 0.36 + 0.00
11p15.1
LDHA
LDHC
− + − 0.28 − + + + + + 0.28 + 0.21 + + + + − − −
− + − 0.27 − + + 0.26 + + 0.42 0.31 0.37 0.30 + + + − − −
14q23.2
HIF1A 0.34 0.46 − + 0.52 + − − − − + − − − 0.21 − − 0.34 0.38 −
15q22.2
CA12 0.31 0.33 + + − + − + 0.39 + + − − − − + + 0.19 − −
17q21.2
ACLY − − − − 0.31 + + + − − 0.36 0.33 0.34 0.30 + + − − − −
17q25.3
SLC16A3 + 0.21 − − 0.20 + − 0.27 0.20 0.23 + − − − − + + + + −
19q13.33
GYS1 + + 0.30 0.33 + 0.21 − − + − + + + + 0.26 + − + − −
Similar patterns for
the potential
amplicons
9 of 11 MTB/GF genes 8 of 11 MTB/GF genes 7 of 11 MTB/GF genes 9 of 11 MTB/GF genes
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Fig. 6. Patterns of functional relevance in the correlations between metabolic genes and oncogenes. (a) A pattern attributed to genes whose expressions protect glycolysis in acidic con-
ditions, possibly to supra-physiologic limits. Positive correlations of the ENO1 transformed expressions ofmetabolic genes (CA3, CA12, LDHA, LDHC, and SLC16A3(orMCT4)) occurredwith
CN of oncogenes (EGFR,MOS, RNF139,MYC, PIK3C2B, CYP27B1, and CDK4). Those supported by signiﬁcant associations (Wilcoxon Rank Sum, Section 3.6) are indicated by solid red arrows
and trends by black striped arrows. Complexity within a potential 8q amplicon is indicated by strong correlation (r=0.98) betweenMOS andMYC but weaker correlations between each
of them and intervening RNF139. (b) A pattern attributed to non-aerobic glycolysis operating in intermittent avascular conditions based on previous studies of glycolytic-dependent glio-
blastoma cell migration [9,11], involving ENO1 transformed expressions of metabolic genes, ACLY, GYS1, LDHA, and LDHA, was identiﬁed by shared positive correlations with CN of onco-
genes, EGFR, CCND1, CTTN, FGF3, FGF4, and CCND2. (c) The CN gain of XIAP revealed an opposing pattern for metabolic genes' expressions. The signiﬁcant association (Wilcoxon Rank Sum,
Section 3.6) and a trend are indicated by the solid red and striped black arrows, respectively.
11M.E. Beckner et al. / BBA Clinical 5 (2016) 1–15anoxic stress for 4 h led to increased levels of CAIII, among other
isoforms, in the cerebral cortex, hippocampus, cerebellum, and retina
of piglets [36]. Interestingly, in hepatoma cells overexpression of CA3
by transfection resulted in increased extracellular acidiﬁcation,
anchorage-independent growth and invasiveness with elevated focal
adhesion kinase (FAK) and Src activity [37]. Increased EGFRvIII expres-
sion has been associated with protein levels of CAIII and poor survival
in glioblastomas [38]. Previously, we detected four phosphorylated
tyrosine (pY) residues (Y845, Y992, Y1045, and Y1068) in EGFR within
pseudopodia of migrating glioblastoma cells [39]. The pseudopodia
constitute a relatively glycolytic subcellular domain compared to
whole cells [1]. Others have proposed that EGFR's “Y/pY ﬁngerprints”
deﬁned in time courses may “encode” acid–base disturbances [40].
This study of glioblastomas showed that CN gains in EGFR of 2.00-fold
or greater signiﬁcantly associated with expression levels of CA3,transformed by concurrent levels of ENO1. Thus, the metabolic role
played by carbonic anhydrase III in glioblastomas is possibly inﬂuenced
by effects due to gains in CN of EGFR and its signaling on CA3's expres-
sion levels.
The other signiﬁcant associations found in this study were for CN of
oncogenes and gender with CA12 that encodes the transmembrane
carbonic anhydrase, CAXII. Gains in CN of RNF139, lack of gains in XIAP,
and male gender associated signiﬁcantly with expression of CA12 in
this study's glioblastomas. Interestingly, the two ampliﬁed oncogenes,
RNF139 and XIAP, that had opposing associations with expression of
CA12, both encode RING proteins that are E3 ubiquitin ligases [41–44].
Previously CAXII has been found in multiple types of tumors with
expression results in some suggesting a malignant role. Immunohisto-
chemistry demonstrated CAXII in oncocytomas and clear-cell carcino-
mas of the kidneys [45] and ovarian carcinomas [46]. In assays of
Fig. 7.Expressions of carbonic anhydrase genes,CA3 and CA12, transformedby ENO1, associated signiﬁcantly inWilcoxon Rank Sumanalyseswith CNchanges and gender in glioblastomas.
(a) Transformed CA12 expression associated signiﬁcantly with CN gains of RNF139 that were 2.00-fold or greater, lack of a 2.00-fold or greater CN gain in XIAP, and with male gender.
(b) Transformed CA3 expression associated signiﬁcantly with CN gains of EGFR that were 2.00-fold or greater. The red and blue dashed lines among the data points indicate the medians
for each data group as indicated.
12 M.E. Beckner et al. / BBA Clinical 5 (2016) 1–15hypoxic colon adenocarcinoma cells, silencing of CA9 alone led to a 40%
reduction in xenograft tumor volumewith accompanying up-regulation
of CA12mRNA levels, whereas silencing of both CA9 and CA12 led to a
greater (85%) reduction in tumor volume. Also, when CA9was silenced
in vivo, therewas an increase in the amount of CAXII shownwith immu-
nostaining [47]. Gene knockdown studies of CA12 in breast carcinoma
cells decreased their invasiveness that was restored by overexpressing
CA12 [48]. Protein expression of CAXII in oral squamous carcinoma has
been associated with more advanced clinical stages, larger tumor size,
recurrence, and poorer prognosis [49]. Both CA9/CAIX and CA12/CAXII
have been studied in lung adenocarcinoma cell lines [50]. In colon carci-
noma, CAXII was upregulated on the surfaces of chemoresistant cells
[51]. In diffuse astrocytomas, two forms of CAXII occur derived from al-
ternative splicing. Immunoreactivity for CAXII was found in 98% of 363
astrocytomas and its increased expression correlatedwith higherWorld
Health Organization (WHO) grade, older age, and poorer prognosis in-
dependent of patient age and WHO grade [52]. Our selection of CA12
as a gene from the large carbonic anhydrase family to study was based
partly on signiﬁcantly poorer patient survival at high levels of expres-
sion in glioblastomas found in the REMBRANDT database during
2007–2008 [8].
Statistically signiﬁcant associations found in our study included
greater expression of CA12 (transformed by ENO1) occurring with
2.00-fold or greater CN of RNF139, previously known as TRC8 for “trans-
location in renal carcinoma”. RNF139 occurs as a chromosomal translo-
cation, t(3;8)(p14.2;q24.1) in some familial renal cancers [53–55] and
another RNF139 translocation, t(8;22)(q24.13;q11.21) has been report-
ed in a dysgerminoma [56]. In clear cell renal carcinomas, RNF139 has
been thought to act as a tumor suppressor [41,42,57–59]. However,
RNF139 is expressed in non-renal tissues, including brain [60], and
gains in the expression and CN of RNF139 have recently been noted instudies that include non-renal tumors. In a refractory cancer gene set in-
teraction network (113 cancer patient samples) annotated with tissue
type speciﬁcity, RNF139was overexpressed in 9 of 16 pancreas samples,
p= 0.0085, compared to normal tissue samples [61]. Also, RNF139was
one of three predicted driver genes in cancer shared among breast, mel-
anoma, and liver cancers based on a computational method that ana-
lyzed CN aberrations in human cancer genomes [62]. A study on
primary oral tumor samples and nearby tumor-free tissues identiﬁed
RNF139 among a group of 14 genes exhibiting CN gains out of 133
cancer-related genes [63]. Increases in RNF139 gene expression were
found in comparisons of Barrett esophagus (precancerous) and esopha-
geal adenocarcinomas with normal esophagus [64]. Our study suggests
that CN gains in RNF139 found in glioblastomas are associated with the
increased expression of CA12.
Another statistically signiﬁcant association for an oncogene in our
study occurred for the greater expression of CA12 (transformed by
ENO1) when CN of XIAP (X-linked inhibitor of apoptosis, previously
known as BIRC4) was less than 2.00-fold. In other words, there was a
negative correlation with CN gains in XIAP for increased expression of
CA12. Others have found XIAP and two other inhibitors of apoptosis in
twelve malignant glioma cell lines [65]. Although XIAP is known as an
endogenous repressor of the terminal caspase cascade in apoptosis, it
may also be involved in other activities, including modulation of signal
transduction and protein ubiquitination. XIAP is synthesized during
conditions of stress that inhibit protein synthesis [66]. When XIAP is
translated by a mechanism involving an internal ribosome entry site
(IRES), interactions of XIAP IRES with MDM2 may affect stabilization
of itself and MDM2. Interestingly, because XIAP can induce autophagy,
it can have an antitumor effect in early tumorigenesis in contrast to
being an aid for tumor survival in stressful conditions. Therefore, XIAP's
role in tumors has been proposed to be contextual [67]. Mutational loss
Fig. 8. Roles for ampliﬁed oncogenes, EGFR, RNF139, and XIAP, to control pH via access to
the systemic bicarbonate buffer system in aiding glioblastoma cells. Red cells and plasma
in the blood stream (upper panels) remove carbons via CO2 that is exhaled in the lungs.
Transport of CO2/HCO3− occurs in a relay fashion within the circulation. Large amounts
of bicarbonate in the bloodstream buffer protons and levels are maintained via recycling
in the kidneys where the protons carried by bicarbonate are expelled. Ampliﬁed EGFR
and RNF139may enhance expression of CA3 and CA12, respectively, to increase encoded
tumor carbonic anhydrases (lower panel). In contrast, XIAP may reduce expression of
CA12. Lactic acid membrane transporter, MCT4, is encoded by SLC16A3. The edge of a
tumor cell is in the lowest panel. Red cells are depicted with reactions derived from
other diagrams [78–80]. H+ ions (protons) from ATP breakdown during anaerobic
metabolism involving lactic acid is a process explained elsewhere [81].
13M.E. Beckner et al. / BBA Clinical 5 (2016) 1–15of XIAP is responsible for X-linked lymphoproliferative syndrome type 2
[68,69].
Although XIAP's CN could potentially be inﬂuenced by X chromo-
somal inactivation, instead, its CN is normally determined by the
number of X chromosomes. One copy of XIAP in males and two in
females, with no evidence of a CN variation, were found in 400 individ-
uals tested with quantitative PCR in a recent asthma study [13]. Also,
differences in response to cerebral ischemia in stroke according to
gender have been attributed to XIAP's correspondence to chromosomal
dosage [70]. In regard to tumors, increased XIAP demonstrated
with immunohistochemistry in hepatocellular carcinoma specimens
was associated with small tumor size, early tumor stage, and better
relapse-free and overall survival [71]. Also, in a mouse model that
demonstrates progression tomalignant peripheral nerve sheath tumors
(MPNST) from neuroﬁbromas, a loss in CN for XIAPwas found in early
passage cell lines established from the MPNSTs [72]. Accordingly, the
negative correlation and signiﬁcant association for lack of XIAP gains
with expression of CA12 in our study suggests that it may regulate
expression of CA12 to control acidity in tumors. However, this relation-
ship is complex in that there are also reports of several types of tumors,
including gliomas, where targeting XIAP has been suggested for treat-
ment purposes [73–76].
Regulation of pH is an essential requirement for life in that protein
interactions are very sensitive to pH, such as those of phosphofructoki-
nase. Vulnerabilities of phosphofructokinase and other glycolytic
enzymes are being considered as important treatment targets [77].
The access of tumors to the bicarbonate buffer system in the blood-
stream is possibly optimized by oncogenes (Fig. 8). This study identiﬁed
CN gains of EGFR and RNF139, male gender, and lack ofXIAP's CN gains as
having signiﬁcant associations with expressions of carbonic anhydrases
that catalyze interconversions of the bicarbonate buffer's components
within and around tumor cells. Gains in CN for EGFR signiﬁcantly
associatedwith expression of CA3, that encodes an intracellular carbon-
ic anhydrase, CAIII. Gains in RNF139 signiﬁcantly associated with CA12's
expression that encodes CAXII, whose activity is extracellular. The
proposed effects of gains in CN of the three oncogenes are illustrated
(Fig. 8, bottom panel). Gender and lack of CN gains for XIAP may be
factors in tumor biology. The gains in CN for EGFR and RNF139 within
tumors may aid tumors metabolically and potentially can serve as
therapeutic targets to counteract non-physiologic pH changes in tumors.
Also, in tumor cells there is a functional relationship between lactate
dehydrogenases and carbonic anhydrases in that with increasing ATP
via lactate production, there is higher demand for pH regulation medi-
ated by carbonic anhydrases. Accordingly, in this study there was a
trend for CN gains of RNF139 to associate with expression of LDHA. CN
gains of RNF139 also showed a trend for associating with expression of
SLC16A3 (also known as MCT4) that extrudes lactic acid from cells.
Additionally, male gender and the lack of CN gains for XIAP trended pos-
itively with expression of LDHA. For LDHC, a Fisher's Exact test revealed
a signiﬁcant association for its increased expression with any 3.00-fold
or greater oncogene CN gain in this study.
5. Conclusions
The sensitivity of PCR methodologies, selection of metabolic genes
using functional relevance and REMBRANDT data, inclusion of many
known oncogenes to screen, and using ENO1 transformation to adjust
for tumor heterogeneity and obtain supra-glycolytic metabolic gene
expression levels were contributing factors that led to the identiﬁcation
of signiﬁcant associations between oncogene CN changes andmetabolic
gene expression levels in this study. Regulation of pH emerged as a
potential oncogene-mediated advantage for tumor cells so that roles
for oncogenes in controlling tumor pH are compelling to consider in
future treatment regimens. Slight increases in expression of carbonic
anhydrases with rapid catalytic rates due to oncogene CN changes
may provide dramatic advantages for tumors. Our ﬁndings suggestthat oncogenes in glioblastomas increase utilization of the body's vast,
systemic bicarbonate buffering system to aberrantly control pH. Identi-
ﬁcation of participating oncogenes may identify functional subgroups
among glioblastomas in larger studies. These oncogenes, when ampli-
ﬁed, may be culprits that enable malignant metabolism to robustly
energize tumor cells that outcompete normal cells with clinically
important prognostic and therapeutic implications.
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